A novel technology for the production of highly active therapeutic proteins.

Baumeister H, Goletz S. In: DrugPlus international 2004: Vol 03.

GlycoEngineering – a Technology for Production of Glycoproteins.

Baumeister H. In: BioTOPics 2004: Vol 24.

Opportunities with NEMOD & GLYCOTOPE.

Goletz S, Baumeister H. In: R&D FOCUS drugnews 2004: Vol 13

Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin-mediated tumour cell adhesion in vitro.

Zeisig R, Stahn R, Wenzel K, Behrens D, Fichtner I. Biochim Biophys Acta. 2004 Jan 28;1660(1-2):31-40.

Read more
Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen.

Ravn P, Danielczyk A, Jensen KB, Kristensen P, Christensen PA, Larsen M, Karsten U, Goletz S. J Mol Biol. 2004 Oct 29;343(4):985-96.

Read more
Simple separation of DNA in antibody purification.

Christensen PA, Danielczyk A, Stahn R, Goletz S. Protein Expr Purif. 2004 Oct;37(2):468-71

Read more
Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1).

Karsten U, Serttas N, Paulsen H, Danielczyk A, Goletz S. Glycobiology. 2004 Aug;14(8):681-92.

Read more